Announced Tue, 14 Apr · 16:06 IST

Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended on 31st March, 2026.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.8%1-day move
₹28.80
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.8-1.0-2.8+0.5-8.4-21.9-8.0+3.1-0.9
Up moveDown movePending
AI summary

Genomic Valley Biotech Ltd has filed a compliance certificate confirming that its Registrar and Share Transfer Agent, Beetal Financial & Computer Services Pvt Ltd, properly handled all dematerialization requests during Q4 (January-March 2026). The certificate verifies that securities received for dematerialization were confirmed to depositories (NSDL/CDSL), listed securities remain on stock exchanges, and share certificates were mutilated and cancelled with depositories substituted as registered owners within the required 15-day timeframe. This is a routine regulatory filing required quarterly under SEBI regulations to ensure proper handling of share dematerialization processes.

Likely market impact

This is a standard regulatory compliance filing with no direct impact on stock price or shareholder value. It confirms the company follows proper dematerialization procedures as mandated by SEBI.